局限期小细胞肺癌（LS-SCLC）新辅助化疗免疫治疗后术后病理完全缓解（pCR）的研究
A study of postoperative pathologic complete response (pCR) following neoadjuvant chemoimmunotherapy in limited-stage small cell lung cancer (LS-SCLC).
摘要(中文译文)
这项回顾性研究评估了新辅助化疗-免疫治疗联合根治性切除术在7例局限期小细胞肺癌（LS-SCLC）患者中的疗效与安全性。患者接受以PD-1/PD-L1抑制剂为基础方案（依托泊苷联合顺铂/卡铂）的新辅助治疗，中位周期数为3个周期，随后行手术切除及辅助化疗-免疫治疗。影像学及生物标志物评估显示肿瘤显著退缩：根据RECIST标准，3例患者达到部分缓解（PR），3例达到完全缓解（CR）。病理学检查证实全部7例患者均达到病理学完全缓解（pCR）。所有患者均成功完成R0切除，围手术期并发症发生率低，无围手术期死亡。中位随访42个月时，6例患者维持持久的无病生存，1例患者在术后16个月出现左锁骨上淋巴结及脑转移，确诊后3个月死亡。治疗相关不良事件可控，以轻至中度为主，无治疗相关死亡。研究结果表明，新辅助化疗-免疫治疗可显著诱导肿瘤退缩、提高可切除性并改善LS-SCLC患者的长期生存，但仍需更大规模的临床试验来验证这些结果并优化这一侵袭性恶性肿瘤的治疗策略。
Abstract
This retrospective study evaluated the efficacy and safety of neoadjuvant chemotherapy-immunotherapy combined with radical resection in 7 patients with limited-stage small cell lung cancer (LS-SCLC). Patients received a median of 3 cycles of neoadjuvant therapy with PD-1/PD-L1 inhibitor-based regimens (etoposide combined with cisplatin/carboplatin), followed by surgical resection and adjuvant chemoimmunotherapy. Imaging and biomarker assessments demonstrated significant tumor regression: 3 patients achieved partial response (PR) and 3 achieved complete response (CR) per RECIST criteria. Pathological examination confirmed complete pathological response (pCR) in all 7 patients. All patients successfully underwent R0 resection with low perioperative complication rates and no perioperative mortality. At median follow-up of 42 months, 6 patients maintained durable disease-free survival, while one patient developed left supraclavicular lymph node and cerebral metastases 16 months post-surgery, resulting in death 3 months after diagnosis. Treatment-related adverse events were manageable, predominantly mild to moderate in severity, with no treatment-related deaths. The findings suggest that neoadjuvant chemoimmunotherapy significantly induces tumor regression, enhances resectability, and improves long-term survival in LS-SCLC patients, though larger-scale clinical trials are needed to validate these results and optimize therapeutic strategies for this aggressive malignancy.
如何引用
AMA
Wang Chunmao, Han Ming, Wang Zitong. A study of postoperative pathologic complete response (pCR) following neoadjuvant chemoimmunotherapy in limited-stage small cell lung cancer (LS-SCLC).. Journal of cardiothoracic surgery. 2026; doi:10.1186/s13019-026-04366-5.
APA
Wang Chunmao, Han Ming, Wang Zitong (2026). A study of postoperative pathologic complete response (pCR) following neoadjuvant chemoimmunotherapy in limited-stage small cell lung cancer (LS-SCLC).. Journal of cardiothoracic surgery. https://doi.org/10.1186/s13019-026-04366-5
GB/T 7714
Wang Chunmao, Han Ming, Wang Zitong. A study of postoperative pathologic complete response (pCR) following neoadjuvant chemoimmunotherapy in limited-stage small cell lung cancer (LS-SCLC).[J]. Journal of cardiothoracic surgery, 2026 doi:10.1186/s13019-026-04366-5.
在 PubMed增强版 阅读全文
翻译全文 · AI 文献问答 · PDF 原文下载 · 引用导出